Floor Backes

Gynecologic oncologist at the James Cancer Hospital at the Ohio State University, clinical trials to improve patients lives. my opinions not OSU’s.

[Floor Backes @FBackesMD]

Congrats to Dr Reed O’Connor and Dr chambers @LAURAJMOULTON on getting the FWC Harold and Barbara Rosenbaum family award @GYNCancer to study probiotic and dietary fiber to potentiate immunotherapy in cervical cancer @osugynonc @OSUCCC_James

[Bhavana Pothuri @BPothuri]

What an amazing day- installation of Floor Backes as the Larry Copeland Professor at OSU James! Thanks Cope for your generosity and tremendous contributions to #gynonc and congrats ⁦@FBackesMD⁩- so well deserved! ⁦@GOG⁩ ⁦@SGO_org⁩ ⁦@IGCSociety⁩ ⁦@acog

[Floor Backes @FBackesMD]

So honored to receive the Larry J. Copeland, MD Endowed Professorship in Gynecologic Oncology @osugynonc @OSUCCC_James

[Floor Backes @FBackesMD]

Platinum sensitivity does not apply in endometrial cancer.
Platinum-free interval (PFI) is associated with response to next therapy but is NOT better for platinum versus no platinum treatment. @gynoncjnls . https://t.co/ybNvQVBCeR

[Floor Backes @FBackesMD]

Drs. Colombo and Ray-Coquard share their thoughts on frontline PARP inhibitor maintenance for ovarian cancer and differences in overall survival and bevacizumab use . Is it study population, the drug, the combination, duration of treatment? #ESMO2024 @myESMO @SGO_org

[Floor Backes @FBackesMD]

⁦@BPothuri⁩ and Dr Tom Herzog comment on long term overall survival with niraparib maintenance in the ovarian cancer PRIMA trial and pembro added to adjuvant chemotherapy in endometrial cancer #esmo2024 ⁦@myESMO⁩ ⁦@SGO_org⁩ #esmo24

[Floor Backes @FBackesMD]

Dr Antonio Gonzalez summarizes his his distillation of the PICOLLO results presented by @AngelesSecord and Rina-S presented by Dr Elizabeth Lee on FRa targeting ADCs in platinum sensitive and resistant #ovarian cancer #ESMO24 @myESMO @SGO_org #esmo2024

[Floor Backes @FBackesMD]

@DebbieRic23 @SGO_org @myESMO Dr Jean Emmanuel Kurtz comments on TORL-123 (CLDN6) and IBI354 (HER2) ADC development #ESMO24 #esmo2024 @myESMO @SGO_org

[Floor Backes @FBackesMD]

Exciting new options on the horizon for patients with recurrent ovarian, endometrial and cervical cancer : 3 Trop2 targeting ADCs were presented #ESMO2024 with relatively similar response rates (30-40%) and DOR > 6 months.

[Floor Backes @FBackesMD]

@DrKatyMoore puts it all so well together and stresses the importance of predictive biomarkers to inform us which ADC to use for each individual patient and how to sequence them @SGO_org @myESMO #ESMO2024 #ESMO24

[Floor Backes @FBackesMD]

@DrKatyMoore puts it all so well together and stresses the importance of predictive biomarkers to inform us which ADC to use for each individual patient and how to sequence them @SGO_org @myESMO #ESMO2024 #ESMO24

[Floor Backes @FBackesMD]

Dr Joyce Barlin very nicely presented the dose optimization PRESERVE-004/GOG-3081 study of novel CTLA4 gotistobart with pembrolizumab. Preliminary efficacy was encouraging at 26-27% in platinum recurrent ovarian cancer. @myESMO @SGO_org #ESMO2024 #ESMO24

[Floor Backes @FBackesMD]

We have not been able to improve outcomes of PARP inhibitor maintenance in the second line. ICON9 shows no benefit of maintenance olaparib and cediranib over olaparib alone in platinum sensitive recurrent ovarian cancer and increased toxicity @myESMO @SGO_org #ESMO2024 #ESMO24

[Floor Backes @FBackesMD]

Again no benefit of immunotherapy in ovarian cancer . the addition of nivolumab to rucaparib as maintenance therapy for front line ovarian cancer did not results in better survival and increased toxicity. @myESMO @SGO_org #ESMO24

[Floor Backes @FBackesMD]

no OS benefit with niraparib first line maintenance therapy, but survival almost 70 months in HRD! I’m so relieved: no detrimental effect on OS and significant PFS benefit. 3x higher post progression PARPi use may have contributed to lack of OS benefit. @myESMO @SGO_org #ESMO24

[Floor Backes @FBackesMD]

“The most exciting negative study” ! While there was no benefit of pembro added to adjuvant chemotherapy in endometrial cancer, in dMMR pembro decreased the risk of recurrence or death but 70% (HR 0.3) ⁦@myESMO⁩ ⁦@SGO_org⁩ #esmo2024

[Floor Backes @FBackesMD]

avelumab + MTX was suggested as the new standard regimen for low risk GTD. Exciting >95% durable cure rate in stage 1-3, WHO score 1-6. @myESMO @SGO_org #esmo2024

[Floor Backes @FBackesMD]

https://t.co/Wx1a3QOhPn

[Floor Backes @FBackesMD]

Tsalling Bosse shows how AI can help predict recurrence risk and benefit from chemotherapy using clinical information and digital pathology through a novel model HECTOR @myESMO @SGO_org #ESMO2024